The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. (6th August 2018)
- Record Type:
- Journal Article
- Title:
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. (6th August 2018)
- Main Title:
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies
- Authors:
- Namazi, Golnaz
Fajnzylber, Jesse M
Aga, Evgenia
Bosch, Ronald J
Acosta, Edward P
Sharaf, Radwa
Hartogensis, Wendy
Jacobson, Jeffrey M
Connick, Elizabeth
Volberding, Paul
Skiest, Daniel
Margolis, David
Sneller, Michael C
Little, Susan J
Gianella, Sara
Smith, Davey M
Kuritzkes, Daniel R
Gulick, Roy M
Mellors, John W
Mehraj, Vikram
Gandhi, Rajesh T
Mitsuyasu, Ronald
Schooley, Robert T
Henry, Keith
Tebas, Pablo
Deeks, Steven G
Chun, Tae-Wook
Collier, Ann C
Routy, Jean-Pierre
Hecht, Frederick M
Walker, Bruce D
Li, Jonathan Z
… (more) - Abstract:
- Abstract : We identified 67 posttreatment HIV controllers with sustained HIV remission after antiretroviral treatment interruption. Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. Abstract: Background: HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods: Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4 + cell dynamics were compared between posttreatment controllers and noncontrollers. Results: Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions:Abstract : We identified 67 posttreatment HIV controllers with sustained HIV remission after antiretroviral treatment interruption. Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. Abstract: Background: HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods: Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4 + cell dynamics were compared between posttreatment controllers and noncontrollers. Results: Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions: Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission. … (more)
- Is Part Of:
- Journal of infectious diseases. Volume 218:Number 12(2018)
- Journal:
- Journal of infectious diseases
- Issue:
- Volume 218:Number 12(2018)
- Issue Display:
- Volume 218, Issue 12 (2018)
- Year:
- 2018
- Volume:
- 218
- Issue:
- 12
- Issue Sort Value:
- 2018-0218-0012-0000
- Page Start:
- 1954
- Page End:
- 1963
- Publication Date:
- 2018-08-06
- Subjects:
- HIV -- treatment interruption -- posttreatment controller -- HIV rebound -- viral decay
Communicable diseases -- Periodicals
Diseases -- Causes and theories of causation -- Periodicals
Medicine -- Periodicals
Communicable Diseases -- Periodicals
Electronic journals
616.9 - Journal URLs:
- http://jid.oxfordjournals.org/content/by/year ↗
http://www.journals.uchicago.edu/JID/journal/ ↗
http://www.jstor.org/journals/00221899.html ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/infdis/jiy479 ↗
- Languages:
- English
- ISSNs:
- 0022-1899
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5006.700000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14729.xml